Advanced search
Publication Cover
Pathology Volume 33, 2001 - Issue 3
Submit an article Journal homepage
26
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A COMPARISON OF THE SENSITIVITY OF APTT REAGENTS TO THE EFFECTS OF ENOXAPARIN, A LOW-MOLECULAR WEIGHT HEPARIN

Beatrice K. H. Ip, Amanda R. Thomson, Helen T. Moriarty School of Biomedical Sciences, Faculty of Health Studies, Charles Sturt University, Wagga Wagga, NSW, Australia
Pages 347-352 | Published online: 06 Jul 2009

  • Hirsh J, Raschke R, Warkentin T, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 (Suppl): 258-75s.
  • Warkentin TE, Levine MN, Hirsh J, et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. New Engl J Med 1995; 332: 1330-5.
  • Eby C. Editorial: Standardisation of APTT reagents for heparin therapy monitoring: urgent or fading priority? Clin Chem 1997; 43: 1105-7.
  • Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62: 1046-9.
  • Eriksson B, Kalebo P, Anthmyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1991; 73A: 484-93.
  • Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
  • Hirsh J. Rationale for development of low molecular weight heparins and their clinical potential in the prevention of postoperative venous thrombosis. Am J Surg 1991; 161:512-8.
  • Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
  • Hull RD, Pineo GF. Therapeutic use of low molecular weight heparins : knowledge to date and their application to therapy. Semin Thromb Haemost 1994; 20: 339-44.
  • Ten Gate JW, Koopman MMW, Prins MH, Buller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 74: 197-203.
  • Kakkar W. Effectiveness and safety of low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995; 74: 364-8.
  • Weitz JI. Drug therapy: low molecular weight heparins. New Engl J Med 1997; 337: 688-98.
  • Leizorovicz A, Simonneau G, Décousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a metaanalysis. Br Med J 1994; 309: 299-304.
  • Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep vein thrombosis with low molecular weight heparins. Arch Intern Med 1995; 155: 601-7.
  • Breddin HK. Treatment of deep vein thrombosis: is thrombosis regression a desirable endpoint? Semin Thromb Haemost 1997; 23: 179-83.
  • Barrowcliffe TW. Annotation: low molecular weight heparin(s). Br J Haematol 1995; 90: 1-7.
  • Brandt JT. Heparin anticoagulation. In: Koepke JA, editor. Practical laboratory haematology. New York: Churchill-Livingstone, 1991; 433-46.
  • Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Haemost 1990; 16 (Suppl): 12-8.
  • Street A, McPherson J. The new heparins. Aust Prescr 1996; 19: 104-8.
  • Dawes J. Interactions of heparins in vascular environment. Haemostasis 1993; 23 (Suppl 1): 212-9.
  • Young E, Cosmi B, Wietz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
  • Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-46.
  • Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-77.
  • Triplett D. Low molecular weight heparins: pharmacology and clinical applications. Hemoliance Times 1997; 2(3): 1-4.
  • Harenberg J, Giese CH, Dempfle CE, Stehle G, Heene DL. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemost 1988; 60: 377-81.
  • Koepke JA. International committee communications: partial thromboplastin time test - proposed performance guidelines. Thromb Haemost 1986; 55: 143-4.
  • Fay MF, Lang M, Furlan M, Beck EA. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays. Thromb Haemost 1987; 58: 853-5.
  • Gawoski JM, Arkin CF, Bovill T, et al. The effects of heparin on the activated partial thromboplastin time of the college of American Radiologists survey specimens. Arch Pathol Lab Med 1987; 111: 785-90.
  • Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
  • Triple" DA. Laboratory monitoring of heparin therapy. Hemoliance Times 1997; 2(2): 1-4.
  • Taylor N, Exner T. Comparison of some activated partial thromboplastin test (APTT) reagents. Aust J Med Lab Sei 1985; 6: 21-3.
  • Bjornsson TD, Nash P. Variability in heparin sensitivity of APTT reagents. Am J Clin Pathol 1986; 86: 199-204.
  • Shojania AM, Tereault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988; 89: 19-24.
  • Van den Besselaar A, Meeuwisse-Braun J, Bertina M. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23.
  • Favaloro EJ, Grispo L. Comparative evaluation of 17 commercial APTT reagents. Aust J Med Sd 1994; 15: 133-40.
  • Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75: 734-9.
  • Botenus RE, Hughes J, Venturini A, et al. Synthetic phospholipid based activated partial thrombopl astin time APTT reagents that replace traditional animal based reagents. Hemoliance Times 1996; 7: 1-5.
  • Van den Besselaar MAP, Neuteboom J, Meeuwisse-Braun J, Bertina RM. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem 1997; 43: 1215-22.
  • D'Angelo A, Seveso MP, D'Angelo SV, et al. Effect of clot detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297-306.
  • Van den Besselaar MAP, Meeuwisse-Braun J, Strebus A, et al. Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers. Thromb Haemost 1995; 74: 1383-4.
  • Van der Velde EA, Poller L. The APTT monitoring of heparin - the ISTH/ICSH collaborative study. Thromb Haemost 1995; 73: 73-81.
  • Cartwright K, Ip B, Crane G. Patient based ratios in the monitoring of therapeutic heparinisation by APTT. Pathology 1997; 29: 450.
  • Stacy MA, Zebeljan D, Dunlop LC, Rosenfeld D. Strong lupus anticoagulant causes interference with heparin assay. Collected papers and abstracts of the Australian Institute of Medical Scientists (AIMS) Meeting. Hobart, Tasmania, September 1998; 21-5.
  • Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-6.
  • Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thomb Haemost 1994; 72: 330-4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.